ESC 365 - STEP HFpEF trial design and baseline characteristics

HFA Premium Access

STEP HFpEF trial design and baseline characteristics

Session: Late breaking clinical trials: medical therapy

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor M. Kosiborod (Kansas City, US)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

55 presentations

10 followers

4 more presentations in this session

PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event

Speaker: Doctor R. Mentz (Durham, US)

A pre-specified, participant-level pooled analysis of PARAGON-HF and PARAGLIDE-HF

Speaker: Doctor M. Vaduganathan (Boston, US)

DAPA-RESIST clinical trial - Dapagliflozin versus metolazone in heart failure with diuretic resistance

Speaker: Doctor R. Campbell (Glasgow, GB)

Verinurad plus allopurinol for heart failure with preserved ejection fraction: results from the AMETHYST randomized controlled trial

Speaker: Professor A. Voors (Groningen, NL)

Access the full session

Late breaking clinical trials: medical therapy

Speakers: Doctor M. Kosiborod, Doctor R. Mentz, Doctor M. Vaduganathan, Doctor R. Campbell, Professor A. Voors

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources